Priority Allocation of Retained Earnings to Research and Development, New Businesses and New Technologies
First written in FY2017. 16 of 18 entries say "Advanced", first in FY2020. Latest entry: FY2026.
25 other companies' latest entry also says "Advanced".
- FY2026AdvancedAnnual report
「Regarding growth investment, the Company incurred ¥668 million in capital expenditures, mainly in the metal surface treatment agents and equipment, etc. segment, and ¥1,273 million in R&D investment, mainly in the same segment, during the current consolidated fiscal year. For the next consolidated fiscal year, the Company expects capital expenditures of ¥1,904 million and R&D investment of ¥1,427 million.」
Under the policy of allocating funds exceeding the appropriate level of cash on hand to growth investment and other purposes, the Company made capital expenditures of ¥668 million and R&D investment of ¥1,273 million, and disclosed specific plans for the following fiscal year. - FY2026-H1AdvancedAnnual report
「Total R&D expenses for the current interim consolidated accounting period were ¥621 million.」
In connection with the policy of allocating funds to R&D, new businesses and new technology development, the Company disclosed that it recorded R&D expenses of ¥621 million for the interim consolidated accounting period. - FY2025AdvancedAnnual report
「Regarding growth investment, the Company incurred ¥735 million in capital expenditures, mainly in the metal surface treatment agents and equipment, etc. segment, and ¥1,186 million in R&D investment, mainly in the same segment, during the current consolidated fiscal year. For the next consolidated fiscal year, the Company expects capital expenditures of ¥707 million and R&D investment of ¥1,315 million.」
Under the policy of allocating funds exceeding cash on hand to growth investment and other purposes, the Company made capital expenditures of ¥735 million and R&D investment of ¥1,186 million, and also disclosed its plan for the following fiscal year. - FY2025-H1AdvancedAnnual report
「Total R&D expenses for the current interim consolidated accounting period were ¥578 million.」
In connection with the policy of allocating funds to R&D, new businesses and new technology development, the Company disclosed that it recorded R&D expenses of ¥578 million for the interim consolidated accounting period. - FY2024-Q3AdvancedAnnual report
「Total R&D expenses for the third quarter of the current consolidated cumulative period were ¥860 million.」
In connection with the policy of allocating funds to R&D, new businesses and new technology development, the Company disclosed that it recorded R&D expenses of ¥860 million for the cumulative third quarter of the fiscal year. - FY2024-Q2AdvancedAnnual report
「Total R&D expenses for the second quarter of the current consolidated cumulative period were ¥565 million.」
In connection with the allocation of funds to R&D, new businesses and new technology development, the Company disclosed that it recorded R&D expenses of ¥565 million for the cumulative second quarter of the fiscal year. - FY2024-Q1AdvancedAnnual report
「Total R&D expenses for the first quarter of the current consolidated cumulative period were ¥275 million.」
In connection with the allocation of funds to R&D, new businesses and new technology development, the Company disclosed that it recorded R&D expenses of ¥275 million for the cumulative first quarter of the fiscal year. - FY2023AdvancedAnnual report
「Regarding growth investment, the Company incurred ¥394 million in capital expenditures, mainly in the metal surface treatment agents and equipment, etc. segment, and ¥1,096 million in R&D investment, mainly in the same segment, during the current consolidated fiscal year. For the next consolidated fiscal year, the Company expects capital expenditures of ¥1,064 million and R&D investment of ¥1,210 million.」
Under the policy of allocating funds exceeding the appropriate level of cash on hand to growth investment and shareholder returns, the Company made capital expenditures of ¥394 million and R&D investment of ¥1,096 million, and expects to invest ¥1,064 million and ¥1,210 million, respectively, in the following fiscal year. - FY2023-Q2AdvancedAnnual report
「Total R&D expenses for the second quarter of the current consolidated cumulative period were ¥538 million.」
In connection with the allocation of funds to R&D, new businesses and new technology development, the Company disclosed that it recorded R&D expenses of ¥538 million for the cumulative second quarter of the fiscal year. - FY2023-Q1AdvancedAnnual report
「Total R&D expenses for the first quarter of the current consolidated cumulative period were ¥267 million.」
In connection with the allocation of funds to R&D, new businesses and new technology development, the Company disclosed that it recorded R&D expenses of ¥267 million for the cumulative first quarter of the fiscal year. - FY2022-Q3AdvancedAnnual report
「Total R&D expenses for the third quarter of the current consolidated cumulative period were ¥790 million.」
In connection with the allocation of funds to R&D, new businesses and new technology development, the Company disclosed that it recorded R&D expenses of ¥790 million for the cumulative third quarter of the fiscal year. - FY2022-Q2AdvancedAnnual report
「Total R&D expenses for the second quarter of the current consolidated cumulative period were ¥525 million.」
In connection with the allocation of funds to R&D, new businesses and new technology development, the Company disclosed that it recorded R&D expenses of ¥525 million for the cumulative second quarter of the fiscal year. - FY2021AdvancedAnnual report
「The Company defines working capital calculated from the balance sheet (accounts receivable + inventories − accounts payable) as the appropriate level of cash and cash equivalents on hand required for stable management, and will use any excess as a source of funds for growth investment, shareholder returns and other purposes. Regarding growth investment, it invested ¥273 million in capital expenditures, mainly in the Metal Surface Treatment Agents and Equipment segment and other segments, and ¥1,076 million in R&D investment, mainly in the same segments, during the consolidated fiscal year.」
The Company explicitly states that cash on hand exceeding the appropriate level of working capital will be allocated to growth investment and shareholder returns, and disclosed capital expenditures of ¥273 million and R&D investment of ¥1,076 million for the fiscal year. - FY2021-Q3AdvancedAnnual report
「Total R&D expenses for the third quarter of the current consolidated cumulative period were ¥823 million.」
In connection with the policy of prioritizing internal funds and other resources for R&D, new businesses and new technology development, the Company disclosed R&D investment of ¥823 million for the cumulative third quarter of the fiscal year. - FY2021-Q2AdvancedAnnual report
「Total R&D expenses for the second quarter of the current consolidated cumulative period were ¥544 million.」
In connection with the policy of prioritizing internal funds and other resources for R&D, new businesses and new technology development, the Company disclosed R&D investment of ¥544 million for the cumulative second quarter of the fiscal year. - FY2020AdvancedAnnual report
「Regarding growth investment, the Company invested ¥1,467 million in capital expenditures, mainly in the Metal Surface Treatment Agents and Equipment segment and other segments, and ¥1,041 million in R&D investment, mainly in the same segments, in fiscal 2019.」
Regarding the policy of prioritizing the allocation of retained earnings and other funds to growth investment, the Company disclosed fiscal 2019 capital expenditures of ¥1,467 million and R&D investment of ¥1,041 million. For fiscal 2020, it expected capital expenditures of ¥336 million and R&D investment of ¥1,042 million. - FY2019RestatedAnnual report
「The Company will prioritize the use of retained earnings for investments that enhance future corporate value, including R&D, new businesses and the development of new technologies.」
Restates the policy of prioritizing the allocation of retained earnings to R&D, new businesses and new technology development. - FY2017First statedAnnual report
「In addition to building up retained earnings to maintain a sound management base, the Company will prioritize the use of retained earnings for investments that enhance future corporate value, including R&D, new businesses and the development of new technologies.」
Alongside stable dividends and share repurchases, the Company describes a capital allocation policy of building up retained earnings and prioritizing allocation to R&D, new businesses and new technology development.